Product Description
PYC-001 increases expression of the remaining healthy copy of OPA1 to compensate for the protein insufficiency. (Sourced from: https://pyctx.com/disease-areas-adoa/)
Mechanisms of Action: OPA1 Replacer
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: PYC Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for PYC-001](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Arthrogryposis|Optic Atrophies, Hereditary|Optic Atrophy, Autosomal Dominant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Sundew | P1 |
Not yet recruiting |
Optic Atrophies, Hereditary|Arthrogryposis|Optic Atrophy, Autosomal Dominant |
2025-07-01 |
43% |